SSY GROUP (02005.HK): Trustee Purchases 1.2 Million Shares on Open Market
NewTimeSpace News: On 2 September 2026, SSY Group Limited (stock code: 02005) announced that, under the restricted share award scheme adopted on 27 December 2018 and funded by the Company's internal resources, the scheme trustee purchased an aggregate of 1,200,000 shares of the Company on the open market on 2 September 2026, to be held in trust for selected participants.
According to the announcement, the average consideration per share was approximately HKD 2.7187 (exclusive of expenses), with a total consideration of approximately HKD 3,262,400, representing approximately 0.041% of the total issued shares. Following the purchase, the trustee held a balance of 15,380,000 shares, representing approximately 0.521% of the total issued shares. The board will review from time to time and decide at its absolute discretion the number of shares to be granted to selected participants.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SSY GROUP (02005.HK): Trustee purchases 1,000,000 shares under restricted share award scheme for approximately HKD 2.73 million
- SSY GROUP (02005.HK): Trustee Purchases 900,000 Shares for Approximately HKD 2,414,700 under Restricted Share Award Scheme
- SSY GROUP (02005.HK): Gadobutrol injection and indocyanine green for injection approved, enhancing imaging and critical care product portfolio
- SSY GROUP(02005.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 320.32 million, YoY increase of 12.99%
- SSY GROUP (02005.HK): Obtains production registration approval for sodium ozagrel injection, achieving full dosage form coverage